Skip to main content
Equibles

GOLDMAN SACHS GROUP INC

Position in MRK — Merck & Co., Inc.

CIK 886982 NEW YORK, NY
Back to MRK Full portfolio

Position in MRK

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$2,421,844,158
+$385,198,103 QoQ
Shares Held
20,133,379
+4.1% QoQ
Ownership
0.815%
of shares outstanding
% of Portfolio
0.38%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 89.12035580316648.ToString("F0")% Shared 0.20853429521194627.ToString("F0")% None 10.67110990162158.ToString("F0")%

Common Shares in MRK Over Time

Shares Held

Position Value (USD)

Derivatives in MRK

reported options exposure · as of Mar 31, 2026
CallValue
$53,276,441
CallShares
442,900
PutValue
$151,060,182
PutShares
1,255,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $25,307,344,615 across 17 Drug Manufacturers - General names. MRK ranks #4 (9.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 6,340,865 $5,832,137,397
2 JNJ
Johnson & Johnson
 18,057,047 $4,413,864,566
3 ABBV
AbbVie Inc.
 15,145,279 $3,293,946,727
4 MRK
Merck & Co., Inc.
This page 		20,133,379 $2,421,844,158
5 AZN
Astrazeneca PLC
 10,605,842 $2,091,684,157
6 GILD
Gilead Sciences, Inc.
 11,065,214 $1,542,158,873
7 AMGN
Amgen Inc
 4,219,989 $1,484,803,127
8 PFE
Pfizer Inc
 47,105,556 $1,322,724,010

All Filings in MRK

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $151,060,182 1,255,800
2026-03-31 $53,276,441 442,900
2026-03-31 $2,421,844,158 20,133,379
2025-12-31 $82,555,418 784,300
2025-12-31 $2,036,646,055 19,348,718
2025-12-31 $58,156,150 552,500
2025-09-30 $1,260,743,330 15,021,367
2025-09-30 $8,384,607 99,900
2025-09-30 $2,895,585 34,500
2025-06-30 $27,571,428 348,300
2025-06-30 $1,455,883,249 18,391,653
2025-06-30 $14,715,844 185,900
2025-03-31 $4,488,000 50,000
2025-03-31 $5,547,168 61,800
2025-03-31 $1,289,620,694 14,367,432
2024-12-31 $1,701,023,638 17,099,152
2024-12-31 $4,426,860 44,500
2024-12-31 $6,685,056 67,200
2024-09-30 $36,657,168 322,800
2024-09-30 $50,193,520 442,000
2024-09-30 $1,683,700,290 14,826,526
2024-06-30 $25,738,020 207,900
2024-06-30 $1,551,582,303 12,532,975
2024-06-30 $6,833,760 55,200
2024-03-31 $19,225,115 145,700
2024-03-31 $1,538,032,949 11,656,180
2024-03-31 $40,086,410 303,800
2023-12-31 $37,655,508 345,400
2023-12-31 $40,620,852 372,600
2023-12-31 $1,319,820,430 12,106,223
2023-09-30 $22,906,375 222,500
2023-09-30 $1,340,505,460 13,020,937
2023-09-30 $71,756,150 697,000
2023-06-30 $137,325,639 1,190,100
2023-06-30 $1,449,746,457 12,563,883
2023-06-30 $12,612,127 109,300
2023-03-31 $1,450,717,015 13,635,840
2023-03-31 $14,437,123 135,700
2023-03-31 $13,266,833 124,700
2022-12-31 $42,638,085 384,300
2022-12-31 $16,121,035 145,300
2022-12-31 $1,358,708,676 12,246,135
2022-09-30 $1,042,362,029 12,103,600
2022-09-30 $58,931,916 684,300
2022-09-30 $55,409,608 643,400
2022-06-30 $77,932,116 854,800
2022-06-30 $1,191,054,997 13,064,111
2022-06-30 $81,487,746 893,800
2022-03-31 $73,287,060 893,200
2022-03-31 $73,623,465 897,300

Report a Problem

Category
Description
Email (optional, for follow-up)